Antibody data
- Antibody Data
- Antigen structure
- References [108]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
- Other assay [4]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13102 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB2 (HER-2) Monoclonal Antibody (e2-4001), Biotin
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-13102 targets HER-2 in IHC, IP, and WB applications and shows reactivity with Human, mouse, and Rat samples.
- Conjugate
- Biotin
- Antibody clone number
- e2-4001
- Concentration
- 0.2 mg/mL
Submitted references Transposon-activated POU5F1B promotes colorectal cancer growth and metastasis.
Anti-correlation of HER2 and focal adhesion complexes in the plasma membrane.
Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles.
Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis.
Molecular architecture of the ErbB2 extracellular domain homodimer.
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells.
SGK3 is associated with estrogen receptor expression in breast cancer.
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival.
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.
Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine.
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
Immunohistochemical characterization of subtypes of male breast carcinoma.
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy.
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
Leptin augments proliferation of breast cancer cells via transactivation of HER2.
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent.
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Loss of annexin A1 expression in breast cancer progression.
Primary neuroendocrine carcinoma of the breast: a case report.
Primary neuroendocrine carcinoma of the breast: a case report.
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.
An acetylation site in the middle domain of Hsp90 regulates chaperone function.
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
[An analysis of genetic transmission in a father and son with osteosarcoma].
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Decorin prevents metastatic spreading of breast cancer.
Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells.
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures.
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture.
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Simó-Riudalbas L, Offner S, Planet E, Duc J, Abrami L, Dind S, Coudray A, Coto-Llerena M, Ercan C, Piscuoglio S, Andersen CL, Bramsen JB, Trono D
Nature communications 2022 Aug 20;13(1):4913
Nature communications 2022 Aug 20;13(1):4913
Anti-correlation of HER2 and focal adhesion complexes in the plasma membrane.
Weinberg F, Han MKL, Dahmke IN, Del Campo A, de Jonge N
PloS one 2020;15(6):e0234430
PloS one 2020;15(6):e0234430
Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles.
Cianciaruso C, Beltraminelli T, Duval F, Nassiri S, Hamelin R, Mozes A, Gallart-Ayala H, Ceada Torres G, Torchia B, Ries CH, Ivanisevic J, De Palma M
Cell reports 2019 Jun 4;27(10):3062-3080.e11
Cell reports 2019 Jun 4;27(10):3062-3080.e11
Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis.
Zhang Q, Ming J, Zhang S, Li B, Yin L, Qiu X
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2015 Jan;18(1):93-9
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2015 Jan;18(1):93-9
Molecular architecture of the ErbB2 extracellular domain homodimer.
Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, Guo H, Qian W, Hou S, Li B, Rao Z, Lou Z, Guo Y
Oncotarget 2015 Jan 30;6(3):1695-706
Oncotarget 2015 Jan 30;6(3):1695-706
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD, Timme S, Braun JA, Gudernatsch V, Schöpflin A, Bogatyreva L, Geddert H, Faller G, Klimstra D, Tang L, Hauschke D, Werner M, Lassmann S
International journal of cancer 2014 Oct 1;135(7):1517-30
International journal of cancer 2014 Oct 1;135(7):1517-30
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.
Steinkamp MP, Low-Nam ST, Yang S, Lidke KA, Lidke DS, Wilson BS
Molecular and cellular biology 2014 Mar;34(6):965-77
Molecular and cellular biology 2014 Mar;34(6):965-77
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y
Scientific reports 2013;3:1106
Scientific reports 2013;3:1106
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Falchook GS, Moulder SL, Wheler JJ, Jiang Y, Bastida CC, Kurzrock R
Annals of oncology : official journal of the European Society for Medical Oncology 2013 Dec;24(12):3004-11
Annals of oncology : official journal of the European Society for Medical Oncology 2013 Dec;24(12):3004-11
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.
Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L
The oncologist 2012;17(4):492-8
The oncologist 2012;17(4):492-8
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M
Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23(5):1144-1150
Annals of oncology : official journal of the European Society for Medical Oncology 2012 May;23(5):1144-1150
NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.
Manandhar S, Choi BH, Jung KA, Ryoo IG, Song M, Kang SJ, Choi HG, Kim JA, Park PH, Kwak MK
Free radical biology & medicine 2012 May 1;52(9):1773-85
Free radical biology & medicine 2012 May 1;52(9):1773-85
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
Yigit S, Pehlivan FS, Evcim G, Etit D
Pathology, research and practice 2012 Mar 15;208(3):147-50
Pathology, research and practice 2012 Mar 15;208(3):147-50
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF, Polydorides AD
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells.
Li X, Kuang J, Shen Y, Majer MM, Nelson CC, Parsawar K, Heichman KA, Kuwada SK
The Journal of biological chemistry 2012 Jun 29;287(27):23171-83
The Journal of biological chemistry 2012 Jun 29;287(27):23171-83
SGK3 is associated with estrogen receptor expression in breast cancer.
Xu J, Wan M, He Q, Bassett RL Jr, Fu X, Chen AC, Shi F, Creighton CJ, Schiff R, Huo L, Liu D
Breast cancer research and treatment 2012 Jul;134(2):531-41
Breast cancer research and treatment 2012 Jul;134(2):531-41
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM, Mostafa MF, El-Gendi AM
Pathology oncology research : POR 2012 Apr;18(2):459-69
Pathology oncology research : POR 2012 Apr;18(2):459-69
Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival.
Ege CB, Akbulut M, Zekioğlu O, Ozdemir N
Archives of gynecology and obstetrics 2011 Nov;284(5):1231-9
Archives of gynecology and obstetrics 2011 Nov;284(5):1231-9
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.
Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA
European journal of cancer (Oxford, England : 1990) 2011 Jul;47(10):1527-36
European journal of cancer (Oxford, England : 1990) 2011 Jul;47(10):1527-36
Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
Fernand VE, Losso JN, Truax RE, Villar EE, Bwambok DK, Fakayode SO, Lowry M, Warner IM
Chemico-biological interactions 2011 Jul 15;192(3):220-32
Chemico-biological interactions 2011 Jul 15;192(3):220-32
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF
Cancer 2011 Jan 1;117(1):39-47
Cancer 2011 Jan 1;117(1):39-47
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG
British journal of neurosurgery 2011 Dec;25(6):707-13
British journal of neurosurgery 2011 Dec;25(6):707-13
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
Rygiel AM, Milano F, Ten Kate FJ, Bergman JJ, Krishnadath KK
Journal of oncology 2010;2010:382582
Journal of oncology 2010;2010:382582
Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine.
Fisher RD, Ultsch M, Lingel A, Schaefer G, Shao L, Birtalan S, Sidhu SS, Eigenbrot C
Journal of molecular biology 2010 Sep 10;402(1):217-29
Journal of molecular biology 2010 Sep 10;402(1):217-29
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Bollig-Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux CN, Ethier SP
Cancer research 2010 Oct 15;70(20):7862-73
Cancer research 2010 Oct 15;70(20):7862-73
Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling.
Pfister AB, Wood RC, Salas PJ, Zea DL, Ramsauer VP
Journal of cellular biochemistry 2010 Oct 15;111(3):643-52
Journal of cellular biochemistry 2010 Oct 15;111(3):643-52
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R
Journal of translational medicine 2010 Jun 7;8:53
Journal of translational medicine 2010 Jun 7;8:53
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A
Cancer 2010 Jul 15;116(14):3330-7
Cancer 2010 Jul 15;116(14):3330-7
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.
Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J
Cell cycle (Georgetown, Tex.) 2010 Jan 1;9(1):140-6
Cell cycle (Georgetown, Tex.) 2010 Jan 1;9(1):140-6
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA
American journal of clinical pathology 2010 Aug;134(2):303-11
American journal of clinical pathology 2010 Aug;134(2):303-11
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.
Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M
Breast cancer research and treatment 2010 Aug;123(1):51-8
Breast cancer research and treatment 2010 Aug;123(1):51-8
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Aug 15;16(16):4226-35
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Aug 15;16(16):4226-35
Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F, Ren J, Qiu XC, Wang LF, Zhu Q, Zhang YQ, Huan Y, Meng YL, Yao LB, Chen SY, Xu YM, Yang AG
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2284-94
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2284-94
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2266-74
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Apr 15;16(8):2266-74
Immunohistochemical characterization of subtypes of male breast carcinoma.
Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M
Breast cancer research : BCR 2009;11(3):R28
Breast cancer research : BCR 2009;11(3):R28
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Misirlioglu D, Nak D, Ozyigit MO, Nak Y, Akkoc A
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy.
Liu X, Wu J, Zhang S, Li C, Huang Q
Cancer gene therapy 2009 Nov;16(11):861-72
Cancer gene therapy 2009 Nov;16(11):861-72
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, Esteva FJ, Tucker SL, Buchholz TA
The American journal of surgical pathology 2009 May;33(5):759-67
The American journal of surgical pathology 2009 May;33(5):759-67
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT
Archives of pathology & laboratory medicine 2009 May;133(5):775-80
Archives of pathology & laboratory medicine 2009 May;133(5):775-80
A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, Mukherjee A, Sperinde J, Pannu H, Chenna A, DeFazio-Eli L, Pidaparthi S, Badal Y, Wallweber G, Chen L, Williams S, Tahir H, Larson J, Goodman L, Whitcomb J, Petropoulos C, Winslow J
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2009 Mar;18(1):11-21
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2009 Mar;18(1):11-21
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Strumane K, Rygiel T, van der Valk M, Collard JG
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jan 10;27(2):220-6
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jan 10;27(2):220-6
Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH
Molecular cancer research : MCR 2009 Feb;7(2):275-84
Molecular cancer research : MCR 2009 Feb;7(2):275-84
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Gong Y, Sweet W, Duh YJ, Greenfield L, Tarco E, Trivedi S, Symmans WF, Isola J, Sneige N
American journal of clinical pathology 2009 Aug;132(2):228-36
American journal of clinical pathology 2009 Aug;132(2):228-36
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
Ren XL, Xu YM, Bao W, Fu HJ, Wu CG, Zhao Y, Li ZK, Zhang J, Li SQ, Chen WQ, Wang T, Zhang R, Zhang LH, Qian GS, Chen SY, Jia LT, Yang AG
Cancer letters 2009 Aug 28;281(2):134-43
Cancer letters 2009 Aug 28;281(2):134-43
Leptin augments proliferation of breast cancer cells via transactivation of HER2.
Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H
The Journal of surgical research 2008 Sep;149(1):9-14
The Journal of surgical research 2008 Sep;149(1):9-14
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, Longley DB
Cancer research 2008 Oct 15;68(20):8312-21
Cancer research 2008 Oct 15;68(20):8312-21
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Inflammatory Breast Cancer Research Group
Cancer 2008 May 1;112(9):1905-11
Cancer 2008 May 1;112(9):1905-11
Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent.
Pedersen NM, Madshus IH, Haslekås C, Stang E
Molecular cancer research : MCR 2008 Mar;6(3):491-500
Molecular cancer research : MCR 2008 Mar;6(3):491-500
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L
Breast cancer research and treatment 2008 Mar;108(2):183-90
Breast cancer research and treatment 2008 Mar;108(2):183-90
Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J
Oncogene 2008 Jul 24;27(32):4434-45
Oncogene 2008 Jul 24;27(32):4434-45
Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB
Cancer research 2008 Jan 15;68(2):483-91
Cancer research 2008 Jan 15;68(2):483-91
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J
Proteins 2008 Feb 15;70(3):938-49
Proteins 2008 Feb 15;70(3):938-49
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN
Cancer biology & therapy 2008 Dec;7(12):1938-46
Cancer biology & therapy 2008 Dec;7(12):1938-46
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ Jr, Mattingly RR, Hancock CN
Cancer biology & therapy 2008 Dec;7(12):1938-46
Cancer biology & therapy 2008 Dec;7(12):1938-46
Loss of annexin A1 expression in breast cancer progression.
Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF
The Lancet. Oncology 2007 Mar;8(3):203-11
The Lancet. Oncology 2007 Mar;8(3):203-11
Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.
Nash JW, Barrett TL, Kies M, Ross MI, Sneige N, Diwan AH, Lazar AJ
Journal of cutaneous pathology 2007 Jan;34(1):49-54
Journal of cutaneous pathology 2007 Jan;34(1):49-54
An acetylation site in the middle domain of Hsp90 regulates chaperone function.
Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L
Molecular cell 2007 Jan 12;25(1):151-9
Molecular cell 2007 Jan 12;25(1):151-9
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M
Cancer 2007 Feb 1;109(3):496-501
Cancer 2007 Feb 1;109(3):496-501
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, Nkenke E, Vylliotis A, Papakosta V, Lazaris A, Patsouris E
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
[An analysis of genetic transmission in a father and son with osteosarcoma].
Tokatli F, Alas RC, Altaner S, Pala F, Uygun K, Uzal C, Yalniz E
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Karg A, Dinç ZA, Başok O, Uçvet A
Pathology, research and practice 2006;202(8):577-83
Pathology, research and practice 2006;202(8):577-83
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.
Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL
Molecular biology of the cell 2006 Jul;17(7):2931-41
Molecular biology of the cell 2006 Jul;17(7):2931-41
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Hansen MR, Roehm PC, Chatterjee P, Green SH
Glia 2006 Apr 15;53(6):593-600
Glia 2006 Apr 15;53(6):593-600
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE
Clinical & experimental metastasis 2005;22(1):39-46
Clinical & experimental metastasis 2005;22(1):39-46
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 Sep;18(9):1165-75
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 Sep;18(9):1165-75
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Oct 15;11(20):7480-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Oct 15;11(20):7480-9
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L
Cancer research 2005 Nov 15;65(22):10524-35
Cancer research 2005 Nov 15;65(22):10524-35
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT, Metz MZ, Kane SE
Breast cancer research and treatment 2005 May;91(2):187-201
Breast cancer research and treatment 2005 May;91(2):187-201
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 May 1;11(9):3309-14
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 May 1;11(9):3309-14
Decorin prevents metastatic spreading of breast cancer.
Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Iozzo RV
Oncogene 2005 Feb 3;24(6):1104-10
Oncogene 2005 Feb 3;24(6):1104-10
Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells.
Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H
Biochemical and biophysical research communications 2005 Feb 18;327(3):907-14
Biochemical and biophysical research communications 2005 Feb 18;327(3):907-14
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.
Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L
Endocrine-related cancer 2005 Dec;12(4):1059-69
Endocrine-related cancer 2005 Dec;12(4):1059-69
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.
Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
Neoplasia (New York, N.Y.) 2005 Aug;7(8):788-98
CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Aug 15;11(16):5686-93
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Aug 15;11(16):5686-93
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, Carothers Carraway CA, Muller WJ, Carraway KL
Journal of cellular physiology 2005 Apr;203(1):44-53
Journal of cellular physiology 2005 Apr;203(1):44-53
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.
Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC
Cancer cell 2004 Sep;6(3):251-61
Cancer cell 2004 Sep;6(3):251-61
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP
Gynecologic oncology 2004 Jan;92(1):160-6
Gynecologic oncology 2004 Jan;92(1):160-6
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP
Gynecologic oncology 2004 Jan;92(1):160-6
Gynecologic oncology 2004 Jan;92(1):160-6
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Gossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients.
Gossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004 Jan-Feb;14(1):145-51
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J
The Journal of biological chemistry 2004 Feb 6;279(6):4339-45
The Journal of biological chemistry 2004 Feb 6;279(6):4339-45
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS
Cancer 2004 Feb 1;100(3):499-506
Cancer 2004 Feb 1;100(3):499-506
Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures.
Zhang L, Fletcher-Turner A, Marchionni MA, Apparsundaram S, Lundgren KH, Yurek DM, Seroogy KB
Journal of neurochemistry 2004 Dec;91(6):1358-68
Journal of neurochemistry 2004 Dec;91(6):1358-68
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A
Cancer 2003 Sep 1;98(5):1055-60
Cancer 2003 Sep 1;98(5):1055-60
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Nov 15;9(15):5652-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Nov 15;9(15):5652-9
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R
FEBS letters 2003 May 22;543(1-3):76-80
FEBS letters 2003 May 22;543(1-3):76-80
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R
FEBS letters 2003 May 22;543(1-3):76-80
FEBS letters 2003 May 22;543(1-3):76-80
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.
Talukder AH, Mishra SK, Mandal M, Balasenthil S, Mehta S, Sahin AA, Barnes CJ, Kumar R
The Journal of biological chemistry 2003 Mar 28;278(13):11676-85
The Journal of biological chemistry 2003 Mar 28;278(13):11676-85
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Shimizu H, Seiki T, Asada M, Yoshimatsu K, Koyama N
Oncogene 2003 Feb 13;22(6):831-9
Oncogene 2003 Feb 13;22(6):831-9
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells.
Ramsauer VP, Carraway CA, Salas PJ, Carraway KL
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
The Journal of biological chemistry 2003 Aug 8;278(32):30142-7
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, Mikuz G, Ensinger C
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA
Cancer research 2002 Mar 15;62(6):1676-81
Cancer research 2002 Mar 15;62(6):1676-81
Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture.
Stoll SW, Kansra S, Elder JT
The Journal of biological chemistry 2002 Jul 26;277(30):26839-45
The Journal of biological chemistry 2002 Jul 26;277(30):26839-45
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Apr 1;20(7):1800-8
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H, Schmidt LJ, Tindall DJ
Cancer research 2001 Oct 15;61(20):7408-12
Cancer research 2001 Oct 15;61(20):7408-12
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
International journal of radiation oncology, biology, physics 2001 Nov 1;51(3):775-84
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT
Neoplasia (New York, N.Y.) 2001 Jul-Aug;3(4):339-50
Neoplasia (New York, N.Y.) 2001 Jul-Aug;3(4):339-50
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-13102) on SKBR3 Cells.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on membrane enriched extracts (30 µg lysate) of SK-BR-3 (1) and MDA-MB-231 (2). The blots were probed with Anti-ErbB2 Mouse Monoclonal Antibody (Product # MA5-13102, 1 µg/mL dilution) and detected by chemiluminescence using Streptavidin-HRP (Product # N200, 1:10,000 dilution). A 185 kDa band corresponding to ErbB2 was observed in SK-BR-3 but not in MDA-MB-231, which is a negative control for ErbB2. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane using the wet transfer system. The membrane was probed with the relevant primary antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
- Conjugate
- Biotin
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast carcinoma stained with c-erbB-2 antibody using peroxidase-conjugate and AEC chromogen. Note intense cell membrane staining of tumor cells.
- Conjugate
- Biotin
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-13102) on denatured Human SKBR3 Cells.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 2 Co-labeling of focal adhesion markers vinculin or talin with HER2. Direct interference contrast (DIC) and wide field fluorescence images of SKBR3 cells seeded on glass-bottom dishes. The cells were either transfected with eGFP-vinculin (A and B) or transduced with talin- GFP (C) to label focal adhesion spots (GFP signal, magenta arrow heads). HER2 was labeled by biotinylated anti-HER2 affibody coupled to strept-QD (HER2-Aff-QD). (A) The focus was adjusted to the basal side of the cells at the interface with the substrate. Images were acquired using a 63x objective. (B) Similar images as in (A), but with the focus adjusted to apical side of the cell. (C) Images of SKBR3 cells with labeled HER2 and transfected with talin-GFP. Images were acquired using a 40x objective. Colors in merged images: yellow for GFP and cyan for HER2-Aff-QD. Scale bars: 20 mum and 10 mum for the insets.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 3 Analysis of intracellular HER2 labeling and co-labeling with talin confirms HER2 expression at the cell substrate interface. (A and B) Total internal reflection fluorescence (TIRF) microscopy of SKBR3 cells transduced with talin-GFP on glass-bottom dishes analyzed with a 100x oil TIRF optimized objective. The intracellular domain of HER2 was labeled with strept-QD via biotinylated anti-HER2 antibody coupled to strept-QD (HER2-QD). Outlined regions indicate HER2-low expression areas. (C) Control experiment using the same protocol as A and B, but without anti-HER2 antibody. (D) Box plot graph displaying the ratios of talin-GFP to HER2-QD corrected integrated fluorescence intensities (CFI) measured at focal adhesions (left) and HER2-enriched regions (right). (E) Box plot graph displaying the CFI for HER2-QD measured at focal adhesions or at HER2-enriched regions. (D, E) **** for p < 0.001, unpaired, two-tailed t-test, n = 339 for talin spots and n = 95 for HER2-enriched regions, obtained from 16 different cells expressing variable amounts of talin. Box plot graphs show min to max representations with indicated median value with each point representing one measurement. Colors in merged images: yellow for GFP and cyan for strept-QD. Scale bars: 20 mum and 5 mum for insets.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 4 Correlative light- and electron microscopy (CLEM) of intracellularly HER2-QD, and talin-GFP at focal adhesions. (A-E) Example image of a SKBR3 cell grown on a silicon nitride window of a silicon microchip suitable for correlative light- and electron microscopy. Shown are DIC (A), fluorescence images for talin-GFP (B), HER2-QD (C), the fluorescent channel overlay image (D), and an 800x low magnification (low mag.) bright field scanning transmission electron microscopy (STEM) image (E) of the same cell. HER2 low regions are outlined in blue. The rectangle outlined in red indicates the magnified region shown in (F) acquired with dark field STEM and overlaid with the corresponding magnified merge fluorescent image. (G) displays a zoom of the highlighted region in blue in (F). A further magnified region is shown in the inlet (white rectangle). Note that the talin-positive region shows a lower abundance of HER2-QDs (yellow stripe). (H) Box plot graph displaying the ratios of talin-GFP to HER-QD CFIs measured at focal adhesions (left) and HER2-enriched regions (right). (I) Box plot graph displaying the CFI for HER2-QD measured at focal adhesions or at HER2-enriched regions. **** for p < 0.001, unpaired, two-tailed t-test, n = 192 for talin spots and n = 48 for HER2-enriched regions. (J) Box plot graph displaying the HER2-QD density measured from the STEM image for focal adhesion versus non-focal adhesion regions. ** for p < 0.01 unpaired, two-tailed t-test, n = 14 for both tal
- Conjugate
- Biotin